Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

Detalles Bibliográficos
Autores principales: Pandit, Anuja, Bhalani, Nirav, Bhushan, B.L. Shashi, Koradia, Parshottam, Gargiya, Shweta, Bhomia, Vinay, Kansagra, Kevinkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236353/
https://www.ncbi.nlm.nih.gov/pubmed/34193375
http://dx.doi.org/10.1016/j.ijid.2021.06.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236353/
https://www.ncbi.nlm.nih.gov/pubmed/34193375
http://dx.doi.org/10.1016/j.ijid.2021.06.030

Ejemplares similares